
Purpose: To present a unique case of multifocal macular serous retinal detachments in the absence of retinal necrosis. Methods: A single case was reviewed. Results: A 74-year-old man presented with right ocular scotomas and was found to have right macular multifocal serous retinal detachments. This was followed by V1 distribution vesicular rash, pseudodendrites, and mild anterior uveitis consistent with herpes zoster ophthalmicus. The patient was maintained on oral valacyclovir and prednisolone eye drops. Within 2 weeks of his initial presentation, a third cranial nerve palsy developed. The macular serous retinal detachment resolved a month after the onset of his treatment-related symptoms. Conclusions: To our knowledge, this is one of the few case reports describing multifocal macular serous retinal detachment in the absence of retinal necrosis. Further case reports are needed to delineate the natural course of this manifestation.
Purpose: To examine the yearly cost of antivascular endothelial growth factor (anti-VEGF) therapy borne by patients and to assess the major contributors to patient cost. Methods: A retrospective, cross-sectional cost analysis was conducted of 29 250 insured patients in a single practice receiving anti-VEGF injections over a 21-month period between January 1, 2023, and September 30, 2024. Direct costs to the patient were abstracted, including patient copay and patient-responsible portions of imaging, medication, procedure, and visit costs; medication costs were based on average sales price. Transportation cost and opportunity cost associated with missed work were operationalized to estimate indirect costs, using age-stratified employment rates and median earnings from the United States Bureau of Labor Statistics for both patients and accompanying caregivers. Results: The mean (±SD) direct cost per visit was $91.72 ± $22.22. Indirect costs per visit varied by indication, with a mean indirect cost per visit of $97.89 for patients with neovascular age-related macular degeneration (AMD) and $164.44 for patients with diabetic macular edema (DME) for a half day of missed work, and $167.98 and $301.09, respectively, for a full day off work. Indirect costs accounted for 45.37% to 74.86% of total patient cost for a half day off, and 58.76% to 84.50% for a full day off. Relative to the baseline of 12 monthly bevacizumab injections received annually (half-day off scenario), the equivalent total patient cost accrued would correspond to a mean annual number of injections of 9.32 and 10.00 for aflibercept 2 mg, 11.09 and 11.35 for aflibercept 8 mg, and 9.05 and 9.78 for faricimab 6 mg in patients with neovascular AMD and patients with DME, respectively. Conclusions: Patient cost is driven more by visit frequency and its associated indirect costs than by drug price. Less frequent dosing with a more durable agent can therefore lower the total cost experienced by patients despite a higher acquisition price.
Purpose: To characterize subretinal precipitates in epidemic retinitis and assess their clinical significance as a resolving-stage manifestation. Methods: This retrospective observational study included 113 patients with epidemic retinitis, categorized into 2 groups based on the presence or absence of subretinal precipitates. Clinical, imaging, and treatment data were analyzed. A subgroup presenting within 20 days of symptom onset (n = 76) was categorized and underwent additional assessment. Results: Of 113 patients, 33 (29.2%) had subretinal precipitates (group A), and 80 did not (group B). Subretinal precipitates appeared as yellow granular lesions, mostly in the inferior fundus (78.8%). Optical coherence tomography scans of the subretinal precipitates demonstrated associated subretinal fluid (SRF) in 11 (37.9%) of the 29 available cases. In the 18 remaining cases, a predominantly inferior gravitational distribution, and in some eyes crescentic configuration, raised the possibility of previously resolved SRF. Fundus autofluorescence failed to detect subretinal precipitates. In subgroup analyses, those with subretinal precipitates (n = 22) had a larger retinitis area (mean 17.28 mm 2 versus 11.9 mm 2 ; P = .16) and higher proportion of oral corticosteroid use (40.9% versus 24.1%; P = .23) than those without subretinal precipitates (n = 54), but differences were not significant. Similarly, no significant differences between subgroups with and without subretinal precipitates were observed in SRF height, number of retinitis patches, final visual acuity, or time to resolution of retinitis and macular edema (each P > .05). Subretinal precipitates developed after a mean 1.1 months (range, 0.5–2 months) and resolved after a mean 5.3 months (range, 2–10 months). Conclusion: Subretinal precipitates are a notable resolving-stage manifestation of epidemic retinitis that may persist for months. Recognition of their characteristic features, particularly in patients with a recent febrile illness, may facilitate the diagnosis of resolving epidemic retinitis.